Critical Survey: VIVUS (VVUS) versus Its Rivals
VIVUS (NASDAQ: VVUS) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare VIVUS to related businesses based on the strength of its risk, dividends, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares VIVUS and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|VIVUS||$133.40 million||$67.14 million||3.23|
|VIVUS Competitors||$578.59 million||$241.91 million||-6.43|
VIVUS’s competitors have higher revenue and earnings than VIVUS. VIVUS is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares VIVUS and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and target prices for VIVUS and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biopharmaceuticals” companies have a potential upside of 2.36%. Given VIVUS’s competitors higher possible upside, analysts clearly believe VIVUS has less favorable growth aspects than its competitors.
Risk & Volatility
VIVUS has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, VIVUS’s competitors have a beta of 1.24, suggesting that their average share price is 24% more volatile than the S&P 500.
Institutional & Insider Ownership
35.8% of VIVUS shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 3.0% of VIVUS shares are owned by company insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
VIVUS competitors beat VIVUS on 6 of the 10 factors compared.
VIVUS Company Profile
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
Receive News & Stock Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related stocks with our FREE daily email newsletter.